FTSE 100 news / Companies and sectors / Pharma and healthcare / 7 October 2026
Pharma and healthcare: sector news on Wednesday 7 October 2026
Average tone +4.3 (positive) across 5 companies with relevant coverage, from 59 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +7.8 | 36 | Coverage was dominated by the opening of AstraZeneca's $1bn R&D hub in Massachusetts, alongside Citi's higher price target on strong clinical data and the completed $2bn Summit investment. |
| GSK | +7.7 | 11 | Coverage was mainly about positive late-stage trial results for ViiV's long-acting HIV treatment Cabenuva, alongside a potential USD 750 million multiple myeloma deal and the Nuvalent agreement. |
| Smith & Nephew | +7.5 | 7 | Coverage was mainly about the European launch of the Cartiheal Agili-C cartilage repair implant, which reads as a positive product development. |
| Convatec | +6.0 | 3 | Coverage centred on Convatec expanding its USD 200 million share buyback and the launch of its Cure Aqua product, both seen in a positive light. |
| Haleon | −7.7 | 2 | Coverage of Haleon was negative, with JPMorgan cutting its price target to 295p and the shares slipping on growth worries ahead of the company's update. |
Strongest stories in the sector
- +10.0 Citi raises AstraZeneca target to £186 as tozorakimab prospects improve
Citi target raised as tozorakimab prospects improve - +10.0 Citi raises AstraZeneca target price to £186 on improved drug prospects and strong clinical data
Citi raises target to £186 on strong data - +10.0 ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia
ViiV Cabenuva trial meets primary endpoint of superior viral suppression - +10.0 Citigroup raises AstraZeneca price target after strong clinical trial results
Citigroup raises target on strong trial results - +9.3 GSK-owned ViiV succeeds in late-stage trial for HIV therapy
ViiV succeeds in late-stage HIV trial - +9.2 AstraZeneca opens $1B-plus R&D hub in Massachusetts
Major $1bn-plus R&D hub opened - +9.2 GSK's long-acting Cabenuva scores win in unsuppressed HIV
Positive Cabenuva trial win in unsuppressed HIV - +9.2 Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
European launch of cartilage repair implant is a positive product milestone. - −8.7 Why Is Haleon (LSE:HLN) Stock Slipping Today As Growth Worries Build Ahead Of Its Update?
Shares slipping on growth worries before a company update. - +8.3 AstraZeneca Opens Strategic R&D Center in Massachusetts
Strategic R&D centre opened - +8.3 AstraZeneca opens new global strategic R&D center in USA
New global strategic R&D centre in US - +8.3 AstraZeneca Opens New Global Strategic R&D Centre in Cambridge
New global R&D centre opened
Pharma and healthcare: every day · FTSE 100 overview for the day